• Novo powers rare disease startup Therachon to $60M round fiercebiotech
    August 10, 2018
    Therachon has raised $60 million (€52 million) to take a phase 1 rare disease drug deeper into the clinic. The Novo Holdings-led mezzanine round comes six months after Therachon began testing its FGFR3 ligand trap in healthy volunteers.
PharmaSources Customer Service